Platelet Doubling After First Decitabine Cycle Predicts Response and Survival of Myelodysplastic Syndrome Patients

Objective Although the effect of decitabine on myelodysplastic syndrome (MDS) has been demonstrated, merely a proportion of patients respond to therapy, and no well-recognized predictors have been identified. This study was conducted to investigate the effectiveness of decitabine in real-world clini...

Full description

Saved in:
Bibliographic Details
Published in:Current medical science 2022-02, Vol.42 (1), p.77-84
Main Authors: Lu, Ping-fan, Deng, Li-nan, Meng, Fan-kai, Wang, Ying, Xiao, Min, Li, Deng-ju
Format: Article
Language:English
Subjects:
Aged
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - pharmacology
Blood Platelets - drug effects
Decitabine - administration & dosage
Decitabine - pharmacology
Female
Humans
Male
Medicine
Medicine & Public Health
Myelodysplastic Syndromes - drug therapy
Outcome Assessment, Health Care
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Although the effect of decitabine on myelodysplastic syndrome (MDS) has been demonstrated, merely a proportion of patients respond to therapy, and no well-recognized predictors have been identified. This study was conducted to investigate the effectiveness of decitabine in real-world clinical practice, and determine the predictive factors of response and overall survival (OS) in MDS patients. Methods Clinical and pathological data were collected from 94 patients and analyzed. These patients were reclassified according to the 2016 World Health Organization classification criteria, and restratified by International Prognostic Scoring System prognostic scores. The response evaluation was performed according to the 2006 modified International Working Group response criteria. Results In this study, 62% of patients responded to decitabine. Among these patients, 15 patients (16%) obtained complete remission (CR), 15 patients (16%) obtained marrow CR with hematologic improvement (HI), 20 patients (21%) obtained marrow CR without HI, and 8 patients (9%) only obtained HI, and no patient botained partial remission. The OS of the responders was significantly longer than that of non-responders (67 months vs. 7 months, P
ISSN:2096-5230
2523-899X
DOI:10.1007/s11596-022-2533-4